CN101049491A - Application of stomachic pill with cyperus and amomum - Google Patents

Abstract

An application of Chinese medicine 'Stomach-nouring Xiansha pill' in preparing the medicines for treating allergic rhinitis and asthma is disclosed.

Description

The application of XIANGSHA YANGWEI WAN

Technical field

The present invention relates to field of medicaments, be specifically related to the application of XIANGSHA YANGWEI WAN in preparation treatment respiratory system disease especially allergic rhinitis and asthmatic medicament.

Background technology

Allergic rhinitis and asthma are common respiratory system diseases.Allergic rhinitis claim allergic rhinitis again, are the allergic diseases of nasal membrane, and cardinal symptom is that rhinocnesmus, paroxysmal sneeze are shown effect continuously, a large amount of clear water sample nasal mucus, and can cause multiple complications, the original imbedibility material of main diseases, food, contactant; Asthma is known as one of four big pertinacious diseases by world medical circle, be listed in the ten big causes of death, be serious harm people physical and mental healths, weaken a kind of disease of work capacity, and be difficult to obtain radical cure.These two kinds of respiratory system common frdquently encountered diseases, prevalence is respectively about 10% and 1～2%, have common pathology and Clinical symptoms, definite in the world at present two diseases belong to together and are a kind of respiratory tract disease, and Therapeutic Method and medicine are also a lot, major part is to belong to anti symptom treatment, as 17-hydroxy-11-dehydrocorticosterone, receptor antagonist, membrane stabilizer have only the minority etiological treatment, as immunomodulators such as desensitization therapy, Si Qikang, but curative effect is not ideal.

All the time, the effect that people are careful in one's diet in allergic rhinitis, asthma morbidity is a food anaphylaxis, usually the Diet Therapy measure of taking is to get rid of the irritated food of specificity, as: shrimp, Eriocheir sinensis, Lac Bovis seu Bubali etc., yet, it is lower that these factors account for its morbidity overall ratio, rises with whole prevalence, directly not related.Food anaphylaxis just wherein protein play a role, and other composition of food comprises fat, carbohydrate, vitamin, trace element etc. and between them proportionate relationship in allergic rhinitis, effect is out in the cold in the asthma morbidity, pass through series of studies, find allergic rhinitis, the non-irritated factor of the morbidity of asthma and diet is closely related, and from evidence-based medicine EBM, epidemiology and experiment are confirmed, this just proof treat allergic rhinitis and asthma disease becomes a kind of important trend from digestive tract, but also reach this sick pharmaceutical preparation of treatment at present from the digestive tract aspect.So seek effective pharmaceutical preparation from the digestive tract aspect is that very necessity also is very urgent.

Summary of the invention

The objective of the invention is further to develop XIANGSHA YANGWEI WAN in medically new purposes, the especially application in preparation treatment respiratory system disease especially allergic rhinitis and asthmatic medicament.

XIANGSHA YANGWEI WAN comes from Ming Dynasty's Gong Tingxian " Wanbing Huichun, Curative Measures for All Diseases ", composition is: the Radix Aucklandiae, Fructus Amomi, the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, the Rhizoma Pinelliae, Poria, Rhizoma Cyperi, Fructus Aurantii Immaturus, Fructus Amomi Rotundus, Herba Pogostemonis, Cortex Magnoliae Officinalis, Radix Glycyrrhizae, Rhizoma Zingiberis Recens, Fructus Jujubae, it is a kind of low-cost Chinese patent medicine, listing for many years, tradition is applied to diseases such as anorexia, gastral cavilty distension, clinical efficacy is welcome by the patient deeply certainly.But still not about the relevant understanding of the application in preparation treatment allergic rhinitis and the asthmatic medicament.

The invention provides the application of XIANGSHA YANGWEI WAN aspect preparation treatment allergic rhinitis and/or asthmatic medicament.

The invention has the beneficial effects as follows significant, through research repeatedly, clinical observation for many years and summary of experience, find that the digestive tract function obstacle is allergic rhinitis and asthma important risk factor, use XIANGSHA YANGWEI WAN preparation treatment allergic rhinitis and/or asthmatic medicament, can reach the beneficial effect of described allergic rhinitis of treatment and asthma from the digestive tract aspect.So the new purposes of XIANGSHA YANGWEI WAN aspect preparation treatment allergic rhinitis and asthmatic medicament is provided, further excavates motherland's pools of traditional Chinese medicine, thereby develop the Chinese medicine of motherland.

The specific embodiment

In order to understand the present invention better, use XIANGSHA YANGWEI WAN below and carry out testing about the clinical practice of allergic rhinitis and asthma disease, its new application aspect preparation treatment allergic rhinitis and asthmatic medicament is described.

Have for example direct application example such as granule, tablet, oral liquid of oral agents on the embodiment XIANGSHA YANGWEI WAN medical market now.

One, experimental technique: take control experiment method at random

The hospital outpatient allergic rhinitis patients is totally 80 examples, all meets perennial allergic rhinitis's diagnostic criteria that Chinese Medical Association works out.Adopt randomized to be divided into 2 groups, 41 examples are organized in treatment, matched group 39 examples.Use XIANGSHA YANGWEI WAN preparation for treating group, male 21 examples, women 19 examples, 14～57 years old age, average 29.7 ± 10.6 years old, the course of disease 2～6 years, average 3.5 ± 1.8 years; Matched group 39 examples, man's 21 examples, woman's 18 examples, 15～54 years old 28.6 ± 12.3 years old age, the course of disease 2～5 years, average 3.2 ± 1.6 years, all patients all had sings and symptomses such as in various degree sneeze, watery nasal discharge, nasal obstruction, concha nasalis enlargement, and the perennial allergic rhinitis that the classification score standard of symptom, sign is worked out according to Chinese Medical Association diagnoses criterion of therapeutical effect (17) to carry out.There are no significant (P＞0.05) for differences such as patient's sex, age, the course of disease between each group.

Asthma 20 examples.Adopt randomized to be divided into 2 groups, 10 examples are organized in treatment, matched group 10 examples.Use XIANGSHA YANGWEI WAN preparation for treating group, male 6 examples, women 4 examples, 14～57 years old age, average 28.7 ± 11.6 years old, the course of disease 2～6 years, average 3.7 ± 1.8 years; Matched group 10 examples, male 5 examples, women 5 examples, 14～55 years old 29.5 ± 12.3 years old age, the course of disease 2～7 years, average 3.5 ± 1.7 years.

Diagnostic criteria

Comprise standard: asthma, allergic rhinitis patients do not have smoking or stop smoking more than 2 years.

Exclusion standard: gestation, apositia, polyphagia, unstable angina pectoris, arrhythmia, the thyroid pathological changes, symptomatic hepatopathy, gallbladder pathological changes and any serious pathological changes that do not have treatment, insulinize, oral hormone treatment.

Pay special attention to: red tongue, yellow fur patient get rid of.

Two, administrated method and dosage

Therapeutic Method: two groups of equal 2 months of courses of treatment

The treatment group: (1) Chinese patent medicine XIANGSHA YANGWEI WAN granule (each 9 grams changed into after twice, ten five day every day, once a day, and each 9 grams); With

(2) conventional asthma, treating allergic rhinitis.

Matched group: conventional asthma, treating allergic rhinitis.

Conventional treating asthma

Press GINA light, in, heavily handle

Gently: do not need any medicine

In: low dosage sucks glucocorticoid and adds theophylline, conventional therapy dosage

Heavy: as lowly to suck glucocorticoid to middle dosage and add long-acting B ₂Agonist adds theophylline or leukotriene receptor regulator, conventional therapy dosage

Conventional treating allergic rhinitis

Gently: ketotifen every day 1 time, each 1mg to 1.5mg

In: ketotifen every day 1 time, each 1mg to 1.5mg adds 1 spray every day of beclometasone 1 time

Heavy: ketotifen every day 1 time, each 1mg to 1.5mg adds 1 spray every day of beclometasone 2 times

Three, observation project and index

1, observation item

(1) variation of clinical symptoms and sign;

(2) asthma ACT score.

2, criterion of therapeutical effect

Allergic rhinitis: the classification score standard of symptom, sign is diagnosed criterion of therapeutical effect according to the perennial allergic rhinitis that Chinese Medical Association works out ^[2]Carry out, the gained integration calculates curative effect by following formula: integration * 100% before integration decline index=(integration before treating-treatment back integration) treated.Produce effects: integration decline index 〉=66%; Effectively: integration decline index 〉=26%; Invalid: integration decline index＜25%; Produce effects and effective percentage rate are designated as total effective rate.

3, therapeutic outcome

Allergic rhinitis: two groups of curative effect comparative observations are treated after 2 months treatment group produce effects 13 examples, effective 24 examples, invalid 4 examples, total effective rate 90.2%.Matched group produce effects 6 examples, effective 21 examples, invalid 12 examples, total effective rate 69.2%.Two groups of total effective rate differences have significance (P＜0.05).

Two groups of curative effects of table 1 allergic rhinitis relatively

	Produce effects	Effectively	Invalid
				Treatment group (41 example) matched group (39 example)	13 6	24 21	4 12

Asthma: two groups of curative effect comparing differences have significance (P＜0.05)

Table 2 asthma: two groups of curative effects relatively

	Before the treatment	After the treatment	Difference
				Treatment group (10 example) matched group (10 example)	18.3 18.5	23.1 21.7	4.8 3.2

4, side effect

Tangible untoward reaction does not appear in allergic rhinitis, treating asthma group.

5, conclusion

Use cyperus-amomum stomach pill for curing allergic rhinitis, more effective, the safety of asthma.

Claims (1)

1, the application of XIANGSHA YANGWEI WAN aspect preparation treatment allergic rhinitis and/or asthmatic medicament.